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The incidence of diagnosed venous thromboembolism (VTE) has been increasing 
concurrent with advances in technology and medical care that enhance our ability to 
treat pediatric patients with critical illness or complex multiorgan system dysfunction. 
Although the overall incidence of VTE is estimated at 0.07–0.49 per 10,000 children, 
higher rates are observed in specific populations including hospitalized children, those 
with central venous catheters (CVCs) or patients convalescing from a major surgery. 
While the absolute number of pediatric VTE events may seem trivial compared to adults, 
the increasing incidence, associated with increased mortality and morbidity, the avail-
ability of novel therapies, and the impact on the cost of care have made investigation of 
VTE risk factors and prevention strategies a high priority. Many putative risk factors for 
pediatric VTE have been reported, primarily from single-institution, retrospective studies 
which lack appropriate methods for verifying independent risk factors. In addition, some 
risk factors have inconsistent definitions, which vex meta-analyses. CVCs are the most 
prevalent risk factors but have not consistently been assigned the highest level of risk as 
defined by odds ratios from retrospective, case–control studies. Few risk-assessment 
models for hospital-acquired pediatric VTE have been published. Some models focus 
exclusively on hospitalized pediatric patients, while others target specific populations 
such as patients with cancer or severe trauma. Multicenter, prospective studies are 
needed to identify and confirm risk factors in order to create a pediatric risk-assessment 
tool and optimize preventive measures and reduce unintended harm.
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inTRODUCTiOn
Understanding and intervening on preventable factors that provoke venous thromboembolism 
(VTE) in pediatrics is a leading initiative for children’s hospitals (1). As the second leading cause of 
hospital-acquired morbidity (preventable harm) for children in the U.S., VTE significantly increases 
hospitalization costs. Using the nationwide inpatient sample, one recent analysis estimated increased 
mean hospital costs of $27,686 and mean length of stay (LOS) extension of 8.1 days in children with 
hospital-acquired VTE (HA-VTE) compared to controls (2).
The foundation of our current knowledge of pediatric VTE has emerged primarily through 
registries, administrative databases, and retrospective cohort studies (3–8). Differences in the 
patient population included and analysis make comparison of these studies challenging. The relative 
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contributions of genetic, anatomic, and acquired risk factors in 
pediatrics have been less studied than in adults (9, 10). Sequelae 
of VTE, namely post-thrombotic syndrome (PTS) and recurrence 
risk, have not been fully investigated in children, but efforts to 
standardize outcome measures are underway (11–13). This pedi-
atric VTE compendium contains mini-reviews on VTE in the 
setting of cancer, congenital heart disease, inflammatory states, 
central venous catheters (CVCs), trauma, and thrombophilia. 
This mini-review will focus on epidemiology of pediatric VTE 
as well as patient and acquired risks. For additional discussion 
of pediatric VTE in a specific disease or clinical state, see the 
accompanying mini-reviews.
inCiDenCe
The estimated incidence of pediatric VTE in developed countries 
ranges from 0.07 to 0.49 per 10,000 children (3, 14). VTE rates 
are notably higher in hospitalized children, 4.9–21.9 per 10,000 
hospital admissions (3, 14, 15). A bimodal distribution is evi-
dent. The most prominent peak is in early infancy accounting 
for up to 20% of pediatric VTE. A second peak occurs during 
adolescence with about 50% of VTE events occurring in children 
11–18 years old. Reported incidence rates vary due to differences 
in study design, cohort inclusion criteria (e.g., all events versus 
symptomatic events, whether neonates are included, and/or if 
age-specific sub-analyses are performed), whether the source 
of information is a database based on billing codes or whether 
radiological confirmation was required for inclusion. For exam-
ple, VTE incidence rates in the Netherlands decreased from 0.14 
per 10,000 children to 0.05 per 10,000 children when neonates 
and non-extremity VTE events were excluded (8).
While the annual burden of thrombosis is greater in adults 
(5.6–16 per 10,000 adults per year) (9, 16), the rate of increase 
in observed incidence in children discharged from tertiary care 
hospitals is notable. Cohort studies targeting HA-VTE demon-
strate a steep rise in incidence, increasing from 0.3 to 28.8 cases 
per 10,000 admissions (1992–2005) in one study and from 34 to 
58 cases per 10,000 admissions (2001–2007) in another (17, 18). 
In contrast to the majority of studies focused on hospital-based 
populations, longitudinal data from a population-based cohort 
study in Québec, QC, Canada found a stable VTE incidence of 
0.29 events per 10,000 person-years in children less than 18 years 
old over the 11-year study period ending in 2004 (5). Notably, 
this study excluded patients less than 1 year of age, and rates were 
calculated based on person-years, as opposed to VTE rate per 
hospital admissions.
The majority of VTE diagnosed in children arise proximal to 
hospitalization and are considered provoked. At least one risk fac-
tor is identified in the majority of patients (19–21). This stands in 
contrast to adults where 30–50% of VTE events are idiopathic or 
spontaneous. CVC-associated VTE predominates in pediatrics. 
In the absence of a CVC, however, location frequency of VTE 
varies by age group. Renal vein VTE comprises a significant 
proportion of events in neonates but is exceedingly rare in older 
children where lower extremity VTE is more likely. Although 
rare, non-extremity VTE in children may arise in portal, splenic, 
mesenteric, pulmonary vessels, or cerebral sinuses (22). No racial 
or ethnic variations have been described, and data on gender dif-
ferences are conflicting.
Pediatric subpopulations have higher VTE incidence 
including children with critical illness, neoplasm, renal disease 
(nephrotic syndrome), congenital heart disease, inflammatory 
bowel disease, or obesity and neonates. Children admitted to the 
intensive care unit (ICU) have a 2% higher risk of VTE if they had 
a short-term CVC and LOS greater than 7 days (23). Occurrence 
of VTE in neonates has been estimated as high as 24 per 10,000 
neonatal intensive care admissions (20). There are presently no 
standard thromboprophylaxis guidelines to mitigate increased 
VTE risk.
RiSK FACTORS
Many patient attributes, medical diagnoses, and elements of 
hospitalized care have been shown or suggested to confer 
HA-VTE risk. Risk factor data are predominately derived 
from single-institution, retrospective cohort, or case–control 
studies (10).
immobility
Absence of consensus on terms altered mobility versus immobility 
creates a challenge when attempting to define the associated risk 
of these states and potential risk reduction with intervention. 
Data from adults show a strong association with various etiolo-
gies of immobility, e.g., post-surgery, plaster cast. Altered mobil-
ity without immobilization also increases risk of symptomatic 
DVT but to a lesser extent than chronic immobilization (24, 25). 
Wells’ criteria for suspected DVT have “recently bedridden for 
3 days or more” in their clinical model (26). The benchmark of 
3 days or more has previously been suggested to confer a high 
degree of risk in pediatrics but has not been prospectively studied 
(27). Multiple studies have implicated altered mobility as a risk 
factor for pediatric HA-VTE. Unfortunately, the granularity to 
understand and compare duration or degree of altered mobility 
among studies is lacking (10).
The Braden Q mobility assessment offers a guide for grading 
mobility (28); however, HA-VTE risk has not been clinically cor-
related to a threshold score. Prospective evaluation of mobility 
rubrics in both children and adults is needed to determine VTE 
risk associated with different mobility states.
infection
Infection is often cited as a risk factor without descriptors of loca-
tion, extent, severity, or inciting organism (29, 30). Occasionally, 
a specified set of infectious conditions (e.g., meningitis, 
bacteremia) are categorized as “infection” (31), or infection 
is dichotomized to focal or systemic. Systemic infections are 
thought to confer higher risk than a focal infection, but this may 
depend on location. For example, otitis media or mastoiditis 
are considered “focal” infections and associated with increased 
risk of cerebral sinus venous thrombosis (32). Similarly, acute 
osteomyelitis has been noted to increase risk of VTE in adjacent 
veins (33). Evaluation of different infectious events and reporting 
confirmation, e.g., culture, is needed to understand VTE risk of 
focal and systemic infections. Concomitant inflammation likely 
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plays a role but may prove difficult to identify independent risk 
separate from the infection.
intensive Care Unit
Recent work has evaluated whether admission to or prolonged stay 
in the ICU is a risk factor for HA-VTE. One study demonstrated 
ICU admission confers independent VTE risk in all pediatric 
patients (27). Two studies in pediatric trauma have demonstrated 
independent VTE risk with ICU admission and ICU stay ≥4 days 
(34, 35). It is likely that ICU admission or prolonged stay is a 
proxy for illness severity and need for additional interventions, 
e.g., CVCs, mechanical ventilation that directly contributes to 
increased VTE risk.
Length of Stay
While recent data have highlighted extended LOS following 
HA-VTE, the mechanism by which prolonged hospitalization 
increases risk is less clear (2). Compounding the challenge are 
differences in analysis. LOS is a continuous variable but has been 
analyzed as both a continuous and a dichotomous variable. In 
two independent retrospective, case–control studies, Branchford 
et al. and Sharathkumar et al. utilized greater than 5 and 7 days, 
respectively, as cutoff values for increased VTE risk based on the 
distribution around the day of hospitalization on which VTE 
occurred (27, 36). Branchford et al. reported the odds of HA-VTE 
increasing by 3% for each additional day beyond 5 days. Pediatric 
trauma-specific literature has demonstrated daily increases in 
HA-VTE risk of 2 and 3% for those admitted with traumatic brain 
injury and general trauma, respectively (37, 38). Future research 
detailing increases in daily risk in the context of concomitant risk 
factors and whether risk can also decrease with elimination of 
other risk factors is lacking but would prove beneficial in under-
standing how LOS impacts VTE risk.
Mechanical ventilation
Mechanical ventilation is emerging as a risk factor, but the 
magnitude of independent risk is unclear. Similar to ICU 
admission, mechanical ventilation may be a proxy for a severely 
ill child. In both trauma and critical care pediatric populations, 
mechanical ventilation has been identified as an independent 
VTE risk factor (36–38). One study observed an increased risk 
with ≥4 days of mechanical ventilation (35). Determining how 
independent risk for VTE increases with each additional day of 
mechanical ventilation, outside of the trauma setting requires 
investigation.
Obesity
Being overweight and obese in pediatrics is defined as body 
mass indices of 85th–94th and ≥95th percentiles, respectively 
(39). Obesity increases VTE risk through a chronic low-grade 
inflammatory state, platelet activation, and endothelial dysfunc-
tion (40). VTE risk due to obesity has been well-characterized in 
adults (41). Minimal pediatric-specific data exist. A retrospective, 
case–control study of 48 children with VTE identified increased 
risk in obese children but not overweight children. This study was 
confounded by frequent co-occurrence of known risk factors in 
obese children and a small sample size (42).
Oral Contraceptive Pills
Venous thromboembolism risk with combined oral contracep-
tive pills (COCPs) has been studied extensively. Estrogen has a 
multitude of mechanisms that increase thrombotic risk includ-
ing increases in pro-coagulant proteins, decreases in counter-
regulatory proteins including protein S and antithrombin, and 
inducing protein C resistance (43). While differences exist 
between route of delivery, type of progesterone, and the doses 
of estrogen and progesterone, the highest level of risk is thought 
to occur in the first 3 months of use and gradually plateaus after 
12  months of use (44). The overall relative risk is threefold 
to fivefold higher than non-users of COCPs. Risk increases 
significantly with concomitant inherited thrombophilia (45). 
Studies examining VTE risk of progesterone-only contracep-
tion are conflicting. Some studies have shown increased risk, 
particularly with depot medroxyprogesterone and high-dose 
oral progesterone, whereas other studies have observed no 
increase in baseline risk, primarily with low-dose oral pro-
gesterone and progesterone-only intra-uterine implantable 
devices (44).
Surgery
Similar to infection, analyzing surgery is problematic given broad 
use of the term. Surgery is often reported as a risk factor without 
defining risk related to a specific procedure or its duration (15, 
46). Procedures may be divided into major or minor, but these 
are neither consistently nor uniformly defined. For example, Van 
Arendonk et al. defined major surgery as involving the nervous, 
respiratory, cardiovascular, digestive, urinary, or musculoskeletal 
systems or spleen (38). Furthermore, not all studies defined the 
time interval between surgery and VTE. Previous work has 
defined VTE risk as 7 and 15 days prior to VTE diagnosis (46, 
47). The duration of surgery has yet to be explored in pediatrics, 
but adult data have shown increasing VTE risk with increasing 
surgery duration (48).
RiSK-ASSeSSMenT MODeLS
Several risk-assessment models have been published for 
pediatric HA-VTE (Table  1) (23, 36, 49–52). Branchford et  al. 
showed independent risk with mechanical ventilation, systemic 
infection, and hospital stay ≥5 days, and that these three factors 
co-occurring yielded a posttest probability of 3.1% for HA-VTE 
(36). Sharathkumar et al. derived six independent risk factors and 
assigned points from beta coefficients in the logistic regression 
model: immobilization (3), LOS ≥  7  days (2), OCPs (2), CVC 
(1), bacteremia (1), and direct ICU admission (0.5). A cumula-
tive score of ≥3 yielded a positive predictive value of 2.45% for 
HA-VTE at a prevalence of 0.71% (27).
Two separate risk-assessment models, one for critically ill chil-
dren and another for non-critically ill children, were created from 
a single institution during the same time period by retrospective, 
case–control study designs (23, 49). In non-critically ill children, 
scores of 8, 7, and ≤6 correlated to risk of HA-VTE of 12.5, 1.1, 
and 0.1%, respectively (49). In critically ill children, scores of 15, 
7–14, and ≤6 correlated to risk of HA-VTE of 8.8, 1.3, and 0.03%, 
respectively (23).
TABLe 1 | Pediatric venous thromboembolism risk-assessment models.
Branchford 
et al. (36)




Reiter et al. (52)a Kerlin et al. (50, 53)
Pediatric 
population
All All ICU Non-ICU ICU All












Literature review Retrospective cohort
N 78:160 173:346 57:171 50:350 389
Validation method Retrospective case–control 
(1:1)
Prospective, observational cohort 
study
Retrospective cohort













LOS ≥ 7 days Immobility >72 h Asymmetric extremity
OCP Infection CVC
CVC Orthopedic surgery Active cancer
Bacteremia Major trauma (ISS > 15) Alternative diagnosisb




Age <1 or >14 years
Obesity
Hypercoagulable state
ICU, intensive care unit; MV, mechanical ventilation; LOS, length of stay; OCP, oral contraceptive pill; CVC, central venous catheters; ISS, injury severity score; BSA, body surface 
area.
aIncluded venous and arterial thromboembolism in their study.
bPresence of this factor results in point reduction from score.
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Kerlin et al. derived an equation that uses 0 or 1 for absence or 
presence of certain factors (53):
VET probability={e^[1.086 (male)+0.595 (asymmetric extremity)
  +0.643 (CVC)+0.549 (active cancer) 1.11 (alternative−  diagnosis)
 2.03]}/{1+e^[1.086 (male)+0.595 (asymmetric − extremity)+0.643 
  (CVC)+0.549 (active cancer) 1.11 (alte− rnative diagnosis) − 2 03. ]}
Reiter et  al. created an ICU-specific risk-assessment model 
(excluded cardiac ICU) for “pre-hospital” and “in-hospital” 
thromboses but included both venous and arterial events (52). 
They derived 12 risk factors from existing literature and weighted 
them equally with 1 point. They found for every 1 point increase 
in total score, the risk of a symptomatic thrombosis increased 
by 1.57-fold (95% confidence interval 0.132–5.49) to 2.12-fold 
(95% confidence interval 0.175–18.34) for “pre-hospital” and 
“in-hospital” thrombi, respectively (p < 0.05) (52).
The model by Prentiss describes levels of risk, Risk Score 1–3, 
but neither details which risk factors comprise the scoring system 
nor their individual point values (51). Additional models have 
been derived for children with acute lymphoblastic leukemia 
(54), pediatric oncology patients with a CVC-related VTE (55), 
and pediatric trauma (56).
To date, a multi-institutional risk-assessment model has 
been lacking in the literature, but current research is underway 
to address this gap (57). The Children’s Hospital-Acquired 
Thrombosis (CHAT) Registry is a multi-institution registry with 
three planned phases of research. The first phase is a retrospectively 
derived risk-assessment model based on logistic regression. There 
are seven institutions contributing cases and controls (1:2), and as 
of January 1, 2017, there are 647 unique subjects with VTE in the 
registry (enrollment ongoing). Once the risk-assessment model is 
developed, it will be prospectively validated it in a separate multi-
institutional study, i.e., phase 2. If validated, a randomized con-
trolled trial investigating the utility of the CHAT risk-assessment 
model will be designed and conducted as the third phase.
MORBiDiTY
Acute VTE sequelae depend on location and severity. 
Pulmonary thromboses may lead to pulmonary hypertension 
or cardiovascular instability. Thrombosis of the superior vena 
cava (SVC) or thoracic vessels may result in SVC syndrome. 
Extremity DVTs induce pain and swelling. VTE in patients 
with renal disease has been associated with 2-fold increase in 
hospital admissions and 10-fold increase in LOS (53). Neonates 
have increased risk of chronic renal insufficiency following 
renal vein thrombosis.
Risk of VTE recurrence has been variably reported but is 
estimated around 10% in children and 3% in neonates (9, 18). 
Comorbidities such as cardiovascular disease, malignancy, and 
neurovascular disorders have been associated with increased 
likelihood of recurrence. Patients with identified thrombophilia 
variants, e.g., prothrombin gene mutation and antithrombin 
deficiency, may also be at increased risk of recurrent VTE. PTS, 
chronic venous insufficiency associated extremity pain, edema, 
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and stasis dermatitis, appear less frequent and severe in children 
(12.4%) compared to adults (30%); however, this likely represents 
underreporting as outcomes studies are limited and most have 
relatively short durations of follow-up (58). PTS occurs most 
commonly in the lower extremities. Recently, the Scientific 
and Standardization Committee of the International Society on 
Thrombosis and Haemostasis recommended use of a pediatric 
modification of the Villalta score for adult PTS to standardize 
reporting in children (11).
MORTALiTY
Venous thromboembolism in children is associated with increased 
mortality. VTE mortality rates of 11.4 per 1,000 child-years have 
been reported, greater than age-specific mortality estimated at 
6.4 per 1,000 child-years in a population-based study conducted 
in Canada (5). This finding is consistent with data from several 
registries that report all-cause mortality in those with VTE of 
9–17%. In one study, over 20% of deaths were noted to occur 
within 30  days of VTE diagnosis (8). The highest mortality 
rate is in the youngest patients. Fortunately, mortality rates 
directly attributed to VTE are low, 1.5–2.2%. Risk of fatality asso-
ciated with pulmonary embolism is less in pediatrics compared 
to adults (59).
COnCLUSiOn
Pediatric VTE is increasing in incidence. Key contrasting points 
between adults and children are that pediatric VTE is more likely 
to be diagnosed in a hospital and have recognizable antecedent 
provocation. As incidence increases, associated morbidities, 
mortality, and health-care costs do likewise. Clearer understand-
ing of pediatric-specific risk factors and validated risk-assessment 
models are needed to reduce preventable harm and investigate 
the efficacy of targeted prophylaxis interventions. A multitude 
of risk factors have been identified for pediatric VTE, but many 
need further elucidation. Similarly, risk-assessment models to 
date provide an initial approach but ultimately lack prospective 
validation and correlation to outcomes. The multi-institution 
CHAT registry is poised to overcome these limitations and 
provide details regarding the magnitude of risk attributable to 
patient, disease, and interventional factors. Initial results are 
anticipated in 2017. If successful, the CHAT Registry may serve 
as the foundation of a risk-stratified, randomized controlled trial 
to evaluate thromboprophylaxis measures in pediatrics.
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